Clients in the media Clients IN the MEDIA

Ensuring your story is visible.
endpoints

Inside the race to make psychedelics ‘mainstream medicines’

When Berra Yazar-Klosinski was wrapping up her PhD in molecular cell and developmental biology at UC Santa Cruz, there was an unassuming little office right down the road, hidden inside a bungalow-style house with a postage-square lawn.

Biotech Startup Fundraising Has Been Resilient, But Investors Are Selective

Venture-capital investment in the biotechnology sector has proved to be resilient so far this year, despite stock-market turbulence and the slower pace of initial public offerings.

PRECISION MEDICINE FOR MENTAL ILLNESS

Alto Neuroscience wants to use EEG brain biomarkers to better match the right treatment to a person’s needs.

biospace

Running the Evolutionary Race against Microbes and Time in AMR

Entasis, which focuses on developing new antibacterial drugs to treat pathogens, utilizes a precision medicine approach to design specific drugs to target specific bacteria.

cell gene

Inside Solid Tumor Therapies With BlueSphere Bio’s CEO Dr. David Apelian

BlueSphere Bio’s CEO Dr. David Apelian explains the difficulties associated with treating solid tumor cancers as well as what the CGT sector needs to get right in the short term and why.

Medicine Maker

Looking Inwards: Solving Gene Therapy Challenges Using the Human Commensal Virome

Ring Therapeutics was launched to take advantage of the viral residents of our bodies – the vast majority of which are anelloviruses. 

Fierce-Biotech

Selecta back in phase 1 gene therapy saddle after clinical hold lift, plans to reboot ‘expeditiously’

The FDA has lifted theclinical hold on Selecta Biosciences’ gene therapy to treat methylmalonic acidemia, a rare disease in children that affects metabolism. The company is now back in the saddle as it preps for a phase 1 trial. 

biospace

Valneva Sets Precedent with Strong Phase III Chikungunya Vaccine Results

France-based biologics company Valneva will be advancing toward U.S. Food and Drug Administration accelerated approval of its specialty vaccine, VLA1553. The single-shot chikungunya vaccine was shown to be safe and effective against mosquito-transmitted chikungunya disease in a published analysis of Phase III results.